Investor Updates
Dutch pharmaceutical company to open plant in Australia
10 May 2013
DSM Pharmaceutical Products will open a new facility in Australia to manufacture drugs for early-stage clinical trials of treatment for arthritis, cancer and other diseases.
DSM Pharmaceutical Products is wholly owned by Dutch company Royal DSM, which has said the plant would make drugs on contract for local companies. The $62 million facility will open in June in Brisbane, the company said.
Royal DSM is the latest company to unveil plans to establish or expand its research and development (R&D) capabilities in Australia in collaboration with the nation’s world-class research organisations and institutions. Aerospace giant Boeing recently opened an R&D facility in Australia, its largest outside the US.
"We are particularly delighted to be bringing our world-class operating ability to the Asia-Pacific region, an important growth area in our strategic development in the biopharmaceutical field; to provide further value to our customers in this region and around the globe," DSM Pharmaceutical Products President and Chief Executive Alexander Wessels said.
The Queensland State Government formed research body BioPharmaceuticals Australia (BPA), which has partnered with DSM to custom-make medicines for the pre-trial and trial stages and operate the new facility in Brisbane. The plant is part of Australia’s $345 million Translational Research Institute, located on Brisbane’s Princess Alexandria Hospital campus.
Netherlands-based Royal DSM is a global science-based company active in health, nutrition and materials. Its products include food, dietary supplements, personal care, pharmaceuticals and medical devices.
More information